Navigation Links
MS drug development agreement based on WEHI's medicinal chemistry
Date:7/2/2008

Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, Merck Serono.

Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. These prospective treatments will be based upon compounds from Bionomics' Kv1.3 program, which WEHI had a fundamental role in developing.

The Kv1.3 program has its origins in the late 1990s, when WEHI's Dr Jonathan Baell and collaborators discovered that certain derivatives of a natural product called khellinone could block a potassium channel called Kv1.3. This potassium channel selectively inhibits autoreactive T cells, such as those that attack the myelin sheath in people with MS.

Dr Baell says, "Our research in this area had a rocky start, but when our first patents were published in 2003, Start-Up Australia approached us with an interest in licensing the intellectual property. This came to fruition in late 2004 through their investee company, Iliad, which was able to resource the medicinal chemistry effort required."

In 2005, Iliad was acquired by Bionomics, which further accelerated progress with the program.

Dr Baell continues, "There was a great meeting of minds between chemists from WEHI and Bionomics, leading to a significant expansion of the patent portfolio. Bionomics also established an in-house biology platform that effectively serviced the whole program."

"During the whole process, every scientist at WEHI and Bionomics maintained a focus upon what we were trying to achieve: a treatment for MS, a debilitating disease that is tragically common among young adults. Our progress and achievements to date demonstrate that with intense tenacity and a collaborative approach, academic drug discovery programs can produce great outcomes."


'/>"/>

Contact: Brad Allan
allan@wehi.EDU.AU
61-393-452-345
Research Australia
Source:Eurekalert

Related medicine news :

1. Ikaria(R) Strengthens Research & Development Team
2. Justice Department Reaches Settlement to Improve Conditions at a Nebraska Developmental Center
3. Contract Research Development Debuts at MD&M Touting Expertise, Innovation and Collaboration
4. The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness"
5. Oaks Development Group Closes on Second San Antonio Project
6. Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
7. Crucial factors in lymphoma development and survival discovered
8. World research leaders gather in Finland to accelerate the development of bioactive paper
9. Healthation CEO Appoints New Senior Vice President of Business Development
10. Penn researchers find key developmental pathway activates lung stem cells
11. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: